New EU stakeholder platform to speed up clinical trials
A new platform is set to facilitate the exchange of information on the optimisation of the electronic reporting system CTIS.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1247 entries already.
Entries by Thomas Gabrielczyk
Ultra-processed foods increase risk for cancer
/in News/by Thomas GabrielczykBritish researchers have linked higher consumption of ultra-processed foods to an increased risk of developing and dying from cancer.
Evotec and Janssen team up in immunooncology
/in News/by Thomas GabrielczykEvotec SE and Janssen Biotech Inc have agreed to co-develop targeted immuno-oncological therapies.
Evidence of deliberate climate damage
/in News/by Thomas GabrielczykA new study adds weight to ongoing legal and political investigations against ExxonMobil for deliberate climate malfeasance.
New polymer can stop biofilm formation
/in News/by Thomas GabrielczykBritish researchers have created a new polymer material that may help to prevent urinary tract infections caused by catheters
Rewind Therapeutics extends Series A financing
/in News/by Thomas GabrielczykWith Sunstone Life Siences A/S as a new investor, Belgian remyelination specialist Rewind Therapeutics has increased its 2018 Series A funding.
Henkel buys FDCA from Avantium NV
/in News/by Thomas GabrielczykBioplastics specialist Avantium N.V. has inked a 5-year agreement to supply Henkel with plant sugar based furandicarboxylic acid , a building block of PEF bioplastics.
Vésale Bioscience wins R&D grant
/in News/by Thomas GabrielczykPhage therapy specialist Vésale Bioscience gas bageds 1.8m from European Innovation Council (EIC) to fight antibiotic resistance (AMR).
Abionyx Pharma announces success in fighting sepsis-triggered AKI
/in News/by Thomas GabrielczykAbionyx Pharma SA has announced positive data from Phase IIa testing of iCER-001, a recombinant apoA-I, as a treatment for septic patients at high risk of developing Acute Kidney Injury […]
BioNTech bags Instadeep for £562m
/in News/by Thomas GabrielczykBioNTech SE will pay £562m in cash to acquire its former partner InstaDeep Ltd. to expand its capabilities in AI-based drug discovery.